CNCR - Loncar Cancer Immunotherapy ETF

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
-0.30 (-1.49%)
At close: 3:54PM EDT
Stock chart is not supported by your current browser
Previous Close20.20
Bid0.00 x 1300
Ask0.00 x 800
Day's Range19.73 - 19.97
52 Week Range16.87 - 25.77
Avg. Volume8,971
Net Assets38.37M
PE Ratio (TTM)N/A
YTD Return6.32%
Beta (3Y Monthly)1.51
Expense Ratio (net)0.79%
Inception Date2015-10-13
Trade prices are not sourced from all markets
  • Cancer-Fighting Stocks & ETF: What You Need to Know

    Cancer-Fighting Stocks & ETF: What You Need to Know

    Many biotech stocks soared after they presented very promising cancer treatment results at the ASCO conference

  • Why Cancer-Fighting Stocks & ETFs Are Soaring

    Why Cancer-Fighting Stocks & ETFs Are Soaring

    The cancer immunotherapy ETF is soaring today as some of its holdings presented very promising results at the ASCO conference. Find out more on the podcast.

  • Morningstar

    Don't Fall for a Good Story

    A version of this article was published in the December 2018 issue of Morningstar ETFInvestor. Download a complimentary copy of Morningstar ETFInvestor by visiting the website. Simple, compelling stories tap into our emotions, hijack our ability to think rationally, and persuade us to pursue investments that are unlikely to perform well. The South Sea Company of early 18th century England exemplifies how a well-spun narrative can cause investors to ignore facts and disrupt their ability to make sound investment decisions.

  • Trump Proposes 2020 Budget: ETFs to Top & Flop

    Trump Proposes 2020 Budget: ETFs to Top & Flop

    Here are the key takeaways from the proposed 2020 budget and their expected impact on ETFs.

  • Best and Worst ETFs of Last Week

    Best and Worst ETFs of Last Week

    After a solid comeback, the momentum on the Wall Street cooled down last week given the round of dismal data across the globe, the European Central Bank's surprise move and dismal U.S. jobs data that renewed threats of global slowdown.

  • ETF Trends

    Healthcare, Biotech ETFs XLV and XBI Slide on FDA’s Uncertain Outlook

    Healthcare companies were among the worst performing stocks Wednesday, with biotechnology sector-specific ETFs taking the brunt of the hit, after FDA Commissioner Scott Gottlieb unexpectedly resigned, ...

  • ETF Trends

    Specialized Biotech ETF Rallies on MacroGenics Positive Trial Results

    A biotechnology sector-specific exchange traded fund specialized in tracking immunotherapy drugmakers bucked the broader market trends and surged Wednesday after MacroGenics (NasdaqGS: MGNX) announced ...